Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the <scp>SURMOUNT</scp> ‐5 trial
HRQoL improved with tirzepatide and semaglutide, with greater improvement in GH with tirzepatide, especially in participants with limited baseline physical function. Participants who lost the most BW showed the greatest improvements in PF, BP, and GH.
Authors
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Chrisanthi A. Karanikas (ORCID: https://orcid.org/0009-0008-0614-8264)
- Elisa Gomez Valderas
- Alpana P. Shukla (ORCID: https://orcid.org/0000-0002-4763-2350)
- Julia G. Fraseur (ORCID: https://orcid.org/0000-0002-7870-5700)
- Julia P. Dunn (ORCID: https://orcid.org/0000-0001-9561-0183)
Institutions
- Eli Lilly (United States) (US)
- Cornell University (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1111/dom.70215
- Citations
- 3
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Eli Lilly and Company